Pharming Group is a biotechnology business based in the US. Pharming Group stocks (PHAR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.04 – an increase of 5.09% over the previous week. Pharming Group employs 277 staff and has a trailing 12-month revenue of around $201.9 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
Global Trading
| Latest market close | $8.26 |
|---|---|
| 52-week range | $6.71 - $12.56 |
| 50-day moving average | $8.47 |
| 200-day moving average | $9.08 |
| Wall St. target price | N/A |
| PE ratio | 48.75 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.16 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $8.26 from 2022-05-23
| 1 week (2022-05-17) | 5.09% |
|---|---|
| 1 month (2022-04-25) | -3.15% |
| 3 months (2022-02-25) | -10.70% |
| 6 months (2021-11-24) | -3.62% |
| 1 year (2021-05-21) | N/A |
|---|---|
| 2 years (2020-05-21) | N/A |
| 3 years (2019-05-21) | N/A |
| 5 years (2017-05-21) | N/A |
Valuing Pharming Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pharming Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pharming Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, Pharming Group shares trade at around 49x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Pharming Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.9 million.
The EBITDA is a measure of a Pharming Group's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $201.9 million |
|---|---|
| Operating margin TTM | 10.17% |
| Gross profit TTM | $177.7 million |
| Return on assets TTM | 3.29% |
| Return on equity TTM | 5.91% |
| Profit margin | 5.42% |
| Book value | $2.80 |
| Market capitalisation | $543.2 million |
TTM: trailing 12 months
We're not expecting Pharming Group to pay a dividend over the next 12 months.
Over the last 12 months, Pharming Group's shares have ranged in value from as little as $6.71 up to $12.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pharming Group's is 1.55. This would suggest that Pharming Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Pharming Group N. V. , a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
Everything we know about the Wytec International IPO, plus information on how to buy in.